A detailed history of Advisor Group Holdings, Inc. transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,259 shares of SWTX stock, worth $49,126. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,259
Previous 1,458 13.65%
Holding current value
$49,126
Previous $54,000 25.93%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$32.04 - $42.76 $6,375 - $8,509
-199 Reduced 13.65%
1,259 $40,000
Q2 2024

Aug 13, 2024

SELL
$36.06 - $47.62 $1,189 - $1,571
-33 Reduced 2.21%
1,458 $54,000
Q1 2024

May 10, 2024

SELL
$36.5 - $52.5 $50,041 - $71,977
-1,371 Reduced 47.9%
1,491 $73,000
Q4 2023

Feb 12, 2024

SELL
$18.94 - $37.24 $13,220 - $25,993
-698 Reduced 19.61%
2,862 $104,000
Q3 2023

Nov 13, 2023

BUY
$23.12 - $31.38 $21,987 - $29,842
951 Added 36.45%
3,560 $82,000
Q2 2023

Aug 10, 2023

BUY
$23.15 - $32.71 $18,103 - $25,579
782 Added 42.8%
2,609 $68,000
Q1 2023

May 12, 2023

SELL
$24.97 - $34.05 $1,348 - $1,838
-54 Reduced 2.87%
1,827 $47,000
Q4 2022

Feb 10, 2023

SELL
$21.73 - $28.72 $3,954 - $5,227
-182 Reduced 8.82%
1,881 $48,000
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $13,881 - $22,844
576 Added 38.74%
2,063 $58,000
Q2 2022

Aug 10, 2022

SELL
$18.36 - $60.07 $936 - $3,063
-51 Reduced 3.32%
1,487 $36,000
Q1 2022

May 04, 2022

BUY
$48.97 - $65.46 $36,384 - $48,636
743 Added 93.46%
1,538 $86,000
Q3 2021

Nov 05, 2021

BUY
$62.66 - $88.26 $33,899 - $47,748
541 Added 212.99%
795 $51,000
Q1 2021

May 13, 2021

BUY
$65.1 - $93.59 $16,535 - $23,771
254 New
254 $19,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.43B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.